News & Updates
RAB001 is currently promoting clinical phase II, striving to achieve the world's first innovative drug (first-in-class) for the treatment of osteonecrosis in China, and to promote the new drug to developed regions such as the United States and Europe for global marketing and sales through commercial cooperation.
